Chalmer M, et al. - Researchers used Polygenic Risk Score in studies of neuropsychiatric disorders to assess prediction of disease status in case-control studies, shared genetic correlation between co-morbid diseases, and shared genetic correlation between a disease and specific endophenotypes. The score provided an opportunity to investigate the shared genetic risk between known and previously unestablished co-morbidities in migraine research, and could lead to better and personalized treatment of migraine if used as a clinical assistant when identifying responders to specific drugs. The genetic relationship between different headache types and migraine endophenotypes could be analyzed using Polygenic Risk Score. Polygenic Risk Score can also assist in determining the pharmacogenetic effects, and perhaps help to predict efficacy of the Calcitonin Gene-Related Peptide monoclonal antibodies that soon become available as migraine treatment.